Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878934 | 0.98 | PPARG (0.32) | PPARGPPARACD274KDM4EALDH1A1 | |
| SCHEMBL862173 | 0.93 | PPARG (0.35) | PPARGPPARACD274KDM4EALDH1A1 | |
| SCHEMBL12060501 | 0.86 | APP (0.33) | — | |
| SCHEMBL878957 | 0.85 | APP (0.33) | — | |
| SCHEMBL862172 | 0.79 | APP (0.34) | — | |
| SCHEMBL862561 | 0.79 | PPARG (0.33) | PPARGPPARA | |
| SCHEMBL4496064 | 0.75 | APP (0.35) | PPARGPPARAKDM4EALDH1A1TSHR | |
| SCHEMBL841485 | 0.73 | ACHE (0.33) | KDM4ETSHRHTT | |
| SCHEMBL862393 | 0.73 | BCHE (0.35) | PPARGPPARAKDM4ETSHR | |
| SCHEMBL8548578 | 0.69 | CTSA (0.45) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | PPARG 4192/4885PPARA 3164/4885CD274 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.